Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment.

[1]  H. Kanetake,et al.  Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence. , 2004, Urology.

[2]  M. Migaldi,et al.  Apoptosis in Prostate Carcinoma before and after Neoadjuvant Therapy with LH‐RH Analog , 2003, Annals of the New York Academy of Sciences.

[3]  M. Gleave,et al.  Androgens and prostate cancer , 2003, World Journal of Urology.

[4]  M. Nishikido,et al.  Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  B. Szende,et al.  Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma , 2001, The Prostate.

[6]  M. Gleave,et al.  Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. , 2001, The Journal of urology.

[7]  T. Kitamura,et al.  Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation , 1999, Cancer.

[8]  J. Chin,et al.  CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. , 1999, Urology.

[9]  Lee,et al.  Neoadjuvant hormonal therapy in carcinoma of the prostate , 1999, BJU international.

[10]  T. H. van der Kwast,et al.  Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. , 1999, Urology.

[11]  A. Schned,et al.  Neoadjuvant androgen ablation for localized prostatic cancer: pathology methods, surgical end points and meta-analysis of randomized trials. , 1998, The Journal of urology.

[12]  M. Soloway,et al.  Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. , 1998, The Journal of urology.

[13]  A. Bergh,et al.  Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer. , 1998, British Journal of Cancer.

[14]  M. Colecchia,et al.  Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. , 1997, Journal of clinical pathology.

[15]  J. Srigley,et al.  Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. , 1996, The Journal of urology.

[16]  Soloway Ms,et al.  Neoadjuvant hormonal treatment before radical prostatectomy. , 1996 .

[17]  L. Cox,et al.  EDITORIAL. REGULATION OF APOPTOSIS BY Bcl‐2 AND ITS RELATED PROTEINS: IMMUNOCHEMICAL CHALLENGES AND THERAPEUTIC IMPLICATIONS , 1996 .

[18]  D. Wood,et al.  Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer , 1995 .

[19]  F. Marshall,et al.  Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. , 1995, Urology.

[20]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[21]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[22]  E. Jones,et al.  Resection margin status in radical retropubic prostatectomy specimens: relationship to type of operation, tumor size, tumor grade and local tumor extension. , 1990, The Journal of urology.

[23]  Goldenberg,et al.  Immunohistochemical Analysis of Radical Prostatectomy Specimens After 8 Months of Neoadjuvant Hormonal Therapy. , 1999, Molecular urology.

[24]  T. Sano,et al.  Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy. , 1998, British journal of urology.

[25]  M. Gleave,et al.  Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. , 1996, The Journal of urology.

[26]  J. Goméz,et al.  Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy. , 1995, Cancer surveys.

[27]  R. Montironi,et al.  Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology. , 1994, Journal of cellular biochemistry. Supplement.

[28]  A. Schally,et al.  Inhibition of growth of experimental prostate cancer in rats by LH‐RH analogs linked to cytotoxic radicals , 1993, The Prostate.